'Potency' Is the Word That Turns an Ad Into a Drug

which exact sentences did FDA call disease claims in the structure/function rule?

FDA named three specific phrases as disease claims in its January 2000 structure/function final rule, spelling out the exact wording instead of leaving advertisers to guess at a theme. We read the preamble text at 65 FR 1000 directly for this page, because the agency's own sentences are dated, public, and rarely quoted in full.

The three: 'Helps restore sexual vigor, potency, and performance,' 'improves performance, staying power, and sexual potency,' and 'builds virility and sexual potency.' FDA said these phrases "are disease claims because they use the term 'potency,' which implies treatment of impotence, a disease."

All three phrases share one word: potency.

None of the three sentences mentions erectile dysfunction, blood flow, or any diagnosis. That's the mechanism worth remembering: how direct compliant supplement ad copy can get turns on connotation, not on whether a page names a condition outright. FDA proved it here with one shared word, not a symptom list.

why does the single word 'potency' cost an advertiser the exemption?

'Potency' fails the exemption because FDA reads it as a synonym for treating impotence, and impotence is a disease under FDA's own definition. Under 21 CFR 101.93(g)(1), FDA defines a disease as damage to an organ, part, structure, or system of the body such that it doesn't function properly. Erectile dysfunction fits that definition without needing anyone to name it.

We read the full ten-trigger list in 21 CFR 101.93(g)(2) before writing this page, and trigger (ii) is the one advertisers miss most. It converts a statement into a disease claim if it describes characteristic signs or symptoms of a specific disease using scientific or lay terminology. 'Potency' qualifies as lay terminology for erectile function, whether or not the copy ever uses the word 'dysfunction.'

Once labeling crosses that line, 21 CFR 101.93(f) removes the fallback. The product becomes subject to regulation as a drug unless the claim is an authorized health claim the product qualifies for — and section seven below shows there isn't one.

what did FDA accept as a lawful arousal, desire, and performance claim?

FDA accepted, in the same paragraph, a sentence built entirely from desire, arousal, and performance. It wrote that "'arouses or increases sexual desire and improves sexual performance' is an acceptable structure/function claim because it does not imply treatment of a disease."

Desire, arousal, and general performance survive; potency, virility, and restoration don't. That's the entire distinction FDA drew in one preamble, and it holds up as the clearest documented line in this niche.

There's a second, narrower opening, and most media buyers overestimate how usable it is. FDA added that if these claims "made clear that they were intended solely for decreased sexual function associated with aging, they could be acceptable structure/function claims." That's the same age-framing logic that lets heartburn and joint copy lean on 'occasional' instead of naming a chronic condition. The word FDA chose was conditional, not automatic. In practice the exception works only if you sacrifice the broad, ageless positioning that makes most ED offers profitable, because explicit aging language narrows exactly the audience most buyers want to keep wide open.

does avoiding the words 'erectile dysfunction' keep copy on the safe side?

No — avoiding the phrase 'erectile dysfunction' doesn't protect the copy, because FTC's implied-claim doctrine reaches meaning, not vocabulary. The agency's Health Products Compliance Guidance states that an advertiser must substantiate an implied disease claim even without any express reference to a disease in the ad.

FTC's own worked examples make the mechanism concrete. A supplement named 'Cold Away,' paired with sneeze-and-cough imagery and text about winter nose-and-throat health, transmits a cold-prevention claim — FTC says the text alone would carry it even with the name and pictures stripped out. A joint cream named 'Arthricure,' paired with a before-and-after photo of an elderly woman using a walker, does the same for arthritis: image plus general wording, no diagnosis word required.

Nothing about ED copy is different.

Buyer targeting carries the same trap in reverse. NIH's MedlinePlus states plainly that erectile dysfunction 'is not a natural part of aging,' even though it 'becomes more common as you get older.' An audience built around men who already believe they have ED is a disease population, no matter how carefully the landing page is worded.

how do product names, pictures, and cited studies create a claim with no sentence at all?

Product names, images, and cited studies can create a disease claim with zero problematic sentences in the body copy, because 21 CFR 101.93(g)(2)(iv) lists all three as independent triggers. FDA's own preamble gives real examples: names like 'Carpaltum,' 'Raynaudin,' and 'Hepatacure' evoke a specific pathology and cross the line, while 'Cardiohealth' and 'Heart Tabs' do not.

The test is whether the name names a disease, not whether it merely sounds medical.

Imagery and citations work the same way. The same subsection covers 'pictures, vignettes, symbols, or other means,' and a cited study only becomes a claim when the labeling as a whole implies treatment. A page can pass a word-by-word compliance check on its headline and still fail on its stock photo or its footnote citation.

We found no ED-specific FDA example of this exact trigger in our fact set — the two documented instances are a cold-and-flu product and a joint cream, not a sexual-health one. Treat the analogy as strong, not identical, until FDA publishes one that names this niche directly.

what happens the moment a claim crosses into disease territory under 101.93(f)?

The product becomes an unapproved new drug the instant the claim crosses, and the standard DSHEA disclaimer doesn't undo it. Under 21 CFR 101.93(f), once labeling bears a disease claim the product becomes subject to drug regulation unless it qualifies for an authorized health claim. The required disclaimer, which starts by stating the claim has not been evaluated by the Food and Drug Administration, only accompanies a lawful structure/function claim, and it can't convert an unlawful one no matter how prominently you print it.

The enforcement record backs this with dollar figures, not hypotheticals. In FTC v. National Urological Group, the Spontane-ES product was advertised as effective for treating erectile dysfunction in 90 percent of men. The court entered final orders in December 2008 totaling $15.8 million against the company and its principals. It rejected both the First Amendment defense and the argument that an existing FDA consent decree barred the case. The endorsing physician, Terrill Mark Wright, M.D., was ordered to pay $15,454 personally for his deceptive endorsement. Three corporate defendants were held liable together as a common enterprise, because the same individuals controlled all of them, shared expenses, and worked together toward profit. Redress reached consumers years later, too: in August 2012 the FTC mailed 153,109 checks worth $40.45 each, more than $6 million in total, to people deceived by the same marketing.

Platform risk compounds the legal risk. Google Ads prohibits, regardless of legality, any product that has been subject to a government or regulatory action or warning — meaning an FDA warning letter kills the ad account permanently, even after you fix the copy.

We could not verify Meta's specific rules for this niche. Transparency.meta.com renders its Advertising Standards client-side and returned no readable text on every Adult Content and Health and Wellness path we tried. Read those two sections directly on Meta's live Ad Standards page before relying on any secondhand description of them, ours included.

is there any authorized health claim to fall back on in this niche?

No — FDA has authorized exactly 12 health claims under the significant scientific agreement standard, and none of them touches sexual function, erectile function, or testosterone. They cover things like calcium and osteoporosis, sodium and hypertension, and five separate claims tied to coronary heart disease, but sexual health isn't on the list at all.

That leaves structure/function claims as the only lawful route into labeling, and it doesn't lower the bar for advertising, because FDA rules the label; FTC rules your ad are two separate regimes running in parallel. FTC's guidance states that "substantiation of health-related benefits will need to be in the form of randomized, controlled human clinical testing," a standard the agency applies whether or not FDA would call the underlying claim lawful.

A supplement can be legal on the label and still be a deceptive ad.

which recurring ED sales-page lines are unusable under this reading?

Six phrasings show up across ED sales pages so often they read like boilerplate, and most of them fail the ed supplement ad copy rules on inspection. The same substitution pattern recurs elsewhere: heartburn copy leans on 'occasional' as its load-bearing word instead of a symptom list. The table below sorts the ED versions into what's usable, what needs the aging frame stated outright, and what has no legal path at all.

One unusable line taints the other five.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Which Nutra Niches Actually Convert on Cold Traffic, Nutra Niches a Beginner Should Not Start In, What Supplements Actually Cost by Niche: The Consumer Price Ladder, Which Nutra Niches Actually Retain: Reorder Behavior by Condition, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.